RAPP Stock Summary and Trading Ideas (Rapport Therapeutics | NASDAQ:RAPP)

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

What symbol and exchange does Rapport Therapeutics shares trade?

Rapport Therapeutics trades on the NASDAQ stock market under the symbol RAPP.

What is Rapport Therapeutics stock price doing today?

As of September 11, 2026, RAPP stock price climbed to $43.62 with 234,380 million shares trading.

What is Rapport Therapeutics's Beta?

RAPP has a beta of 2.17, meaning it tends to be more sensitive to market movements. RAPP has a correlation of 0.23 to the broad based SPY ETF.

How much is Rapport Therapeutics worth?

RAPP has a market cap of $2.09 billion. This is considered a Mid Cap stock.

How much money does Rapport Therapeutics make?

Last quarter Rapport Therapeutics reported $0 in Revenue and -$1.19 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.22.

What are the top ETFs holding Rapport Therapeutics?

The top ETF exchange traded funds that RAPP belongs to (by Net Assets): VTI, VXF, XPH, VTWO, SCHA.

Is Rapport Therapeutics (RAPP) a good investment?

RAPP has outperformed the market in the last year with a return of +88.0%, while the SPY ETF gained +17.4%. In the last 3 month period, RAPP beat the market returning +23.9%, while SPY returned +3.9%. However, in the most recent 2 weeks RAPP has underperformed the stock market by returning -10.6%, while SPY returned -0.7%.

What are the support and resistance levels for Rapport Therapeutics (RAPP)?

RAPP support price is $42.29 and resistance is $44.63 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RAPP shares will trade within this expected range on the day.